Raemaekers J M, Beex L V, Koenders A J, Pieters G F, Smals A G, Benraad T J, Kloppenborg P W
Breast Cancer Res Treat. 1985;6(2):123-30. doi: 10.1007/BF02235743.
Specific estrogen receptor activity (ER) was found in 115 of 175 (66%) tumors of patients treated for primary breast cancer in the period 1974-1981; 60 patients had ER-negative tumors. All patients were under observation for at least 48 months (median 76 months). The 24 patients who received adjuvant chemotherapy as part of their initial treatment, were excluded from the analysis of the disease-free interval (DFI). Groups of patients with ER-positive or ER-negative tumors did not differ significantly in clinical characteristics. Patients with ER-positive tumors had a significantly longer DFI than those with ER-negative tumors only in the first year after initial treatment. After prolonged observation a significant difference in recurrence rates was no longer found. In premenopausal women, the DFI was not different for those with ER-positive compared to those with ER-negative tumors, not even in the first year of observation. However, in postmenopausal women, those with ER-positive tumors had a significantly longer DFI up to 3 years after initial treatment but not thereafter. There was no difference in DFI between the ER-positive and ER-negative groups when the tumor stage was taken into account. It is concluded that the ER status of the primary tumor affects prognosis only on the short term.
1974年至1981年期间，对接受原发性乳腺癌治疗的患者的175个肿瘤进行检测，发现其中115个（66%）肿瘤存在特异性雌激素受体活性（ER）；60例患者的肿瘤ER呈阴性。所有患者均接受了至少48个月的观察（中位时间76个月）。作为初始治疗一部分接受辅助化疗的24例患者被排除在无病生存期（DFI）分析之外。ER阳性或ER阴性肿瘤患者组在临床特征上无显著差异。仅在初始治疗后的第一年，ER阳性肿瘤患者的DFI明显长于ER阴性肿瘤患者。经过长时间观察，不再发现复发率有显著差异。在绝经前女性中，ER阳性肿瘤患者与ER阴性肿瘤患者的DFI没有差异，即使在观察的第一年也是如此。然而，在绝经后女性中，ER阳性肿瘤患者在初始治疗后长达3年的DFI明显更长，但之后则不然。考虑肿瘤分期时，ER阳性和ER阴性组之间的DFI没有差异。得出的结论是，原发性肿瘤的ER状态仅在短期内影响预后。
